癌症基因组图谱中非洲与欧洲血统乳腺癌分子特征及生存比较
基于癌症基因组图谱930例浸润性乳腺癌患者数据,比较154例非洲血统黑人与776例欧洲血统白人的分子特征与生存。黑人患者无乳腺癌间期更差(HR=1.67),基底样和ERBB2富集亚型比例更高,TP53突变更多而PIK3CA突变更少;校正内在亚型后多数分子差异消失,但仍有16个DNA甲基化探针、4个DNA拷贝数片段、1个蛋白和142个差异表达基因。亚型遗传度估计为0.436,超过40%的亚型频率差异可由遗传变异解释。
要点
- 黑人患者无乳腺癌间期较白人差(HR=1.67,95%CI 1.02-2.74,P=.043)。
- 黑人患者基底样(OR=3.80)和ERBB2富集(OR=2.22)亚型比例更高,以Luminal A为参照。
- 校正内在亚型后多数分子差异消失,但基因特征区分黑白患者交叉验证C指数为0.878。
核心结论
- 校正内在亚型频率差异后,癌症基因组图谱数据中黑人与白人之间存在少量基因组差异但有显著的临床生存结局差异。
- 超过40%的乳腺癌亚型频率差异可由遗传变异解释。
- 这些数据可为开发针对黑人女性高发乳腺癌亚型的分子靶向治疗提供基础。
- 研究结果提示个体化风险评估和优化治疗可减少黑人女性侵袭性乳腺癌死亡。
研究设计与样本
- 研究为便利队列,数据来自癌症基因组图谱,纳入浸润性乳腺癌患者的肿瘤与配对正常组织样本(截至2015年9月18日)。
- 共纳入930例乳腺癌患者,包括154例非洲血统黑人患者(诊断时平均[SD]年龄55.66[13.01]岁;98.1%[n=151]为女性)和776例欧洲血统白人患者(诊断时平均[SD]年龄59.51[13.11]岁;99.0%[n=768]为女性)。
- 主要结局指标为无乳腺癌间期、肿瘤分子特征和遗传变异。
主要发现
- 黑人患者较白人患者无乳腺癌间期更差(HR=1.67;95%CI 1.02-2.74;P=.043)。
- 以Luminal A为参照,黑人患者基底样亚型可能性更高(OR=3.80;95%CI 2.46-5.87;P<.001),ERBB2富集亚型可能性更高(OR=2.22;95%CI 1.10-4.47;P=.027)。
- 黑人患者TP53突变较多而PIK3CA突变较少。
- 校正内在亚型后多数分子差异消失,但发现16个DNA甲基化探针、4个DNA拷贝数片段、1个蛋白和142个差异表达基因,基于基因的特征区分黑白患者肿瘤的交叉验证C指数为0.878。
- 基于胚系基因型估计乳腺癌亚型(基底样 vs 非基底样)遗传度为0.436(P=1.5×10−14);基于89个已知易感变异构建的雌激素受体阳性多基因风险评分黑人高于白人(差值0.24;P=2.3×10−5),雌激素受体阴性多基因风险评分黑人远高于白人(差值0.48;P=2.8×10−11)。
临床怎么用
- 作者认为这些数据可为开发分子靶向治疗提供基础,以改善黑人女性高发乳腺癌亚型的临床结局。
- 作者认为个体化风险评估和优化治疗可减少黑人女性侵袭性乳腺癌死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: African Americans have the highest breast cancer mortality rate. Although racial difference in the distribution of intrinsic subtypes of breast cancer is known, it is unclear if there are other inherent genomic differences that contribute to the survival disparities. OBJECTIVES: To investigate racial differences in breast cancer molecular features and survival and to estimate the heritability of breast cancer subtypes. DESIGN, SETTING, AND PARTICIPANTS: Among a convenience cohort of patients with invasive breast cancer, breast tumor and matched normal tissue sample data (as of September 18, 2015) were obtained from The Cancer Genome Atlas. MAIN OUTCOMES AND MEASURES: Breast cancer–free interval, tumor molecular features, and genetic variants. RESULTS: Participants were 930 patients with breast cancer, including 154 black patients of African ancestry (mean [SD] age at diagnosis, 55.66 [13.01] years; 98.1% [n = 151] female) and 776 white patients of European ancestry (mean [SD] age at diagnosis, 59.51 [13.11] years; 99.0% [n = 768] female). Compared with white patients, black patients had a worse breast cancer-free interval (hazard ratio, HR=1.67; 95% CI, 1.02-2.74; P = .043). They had a higher likelihood of basal-like (odds ratio, 3.80; 95% CI, 2.46-5.87; P < .001) and human epidermal growth factor receptor 2 (ERBB2 [formerly HER2])–enriched (odds ratio, 2.22; 95% CI, 1.10-4.47; P = .027) breast cancer subtypes, with the Luminal A subtype as the reference. Blacks had more TP53 mutations and fewer PIK3CA mutations than whites. While most molecular differences were eliminated after adjusting for intrinsic subtype, the study found 16 DNA methylation probes, 4 DNA copy number segments, 1 protein, and 142 genes that were differentially expressed, with the gene-based signature having an excellent capacity for distinguishing breast tumors from black vs white patients (cross-validation C index, 0.878). Using germline genotypes, the heritability of breast cancer subtypes (basal vs nonbasal) was estimated to be 0.436 (P = 1.5 × 10−14). The estrogen receptor–positive polygenic risk score built from 89 known susceptibility variants was higher in blacks than in whites (difference, 0.24; P = 2.3 × 10−5), while the estrogen receptor–negative polygenic risk score was much higher in blacks than in whites (difference, 0.48; P = 2.8 × 10−11). CONCLUSIONS AND RELEVANCE: On the molecular level, after adjusting for intrinsic subtype frequency differences, this study found a modest number of genomic differences but a significant clinical survival outcome difference between blacks and whites in The Cancer Genome Atlas data set. Moreover, more than 40% of breast cancer subtype frequency differences could be explained by genetic variants. These data could form the basis for the development of molecular targeted therapies to improve clinical outcomes for the specific subtypes of breast cancers that disproportionately affect black women. Findings also indicate that personalized risk assessment and optimal treatment could reduce deaths from aggressive breast cancers for black women.
引用
- Huo D, Hu H, Rhie SK, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017. PMID: 28472234. doi:10.1001/jamaoncol.2017.0595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。